Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | ESRRB | O95718 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25966372 | 0.85 | NR1H2 (0.51) | NR1H2NR1H3GPR119AR | |
| SCHEMBL1794578 | 0.85 | CHRNA7 (0.52) | NR1H2NR1H3AR | |
| SCHEMBL38651745 | 0.83 | GPR119 (0.39) | NR1H2NR1H3GPR119AR | |
| SCHEMBL927555 | 0.83 | GPR119 (0.52) | NR1H2GPR119RORCESRRBESR1 | |
| SCHEMBL22015318 | 0.83 | GPR119 (0.52) | NR1H2GPR119RORCESRRBESR1 | |
| SCHEMBL4120182 | 0.82 | CHRNB2 (0.45) | NR1H2NR1H3GPR119AR | |
| SCHEMBL15015937 | 0.82 | CHRNB2 (0.45) | NR1H2NR1H3GPR119AR | |
| SCHEMBL4120180 | 0.82 | CHRNB2 (0.45) | NR1H2NR1H3GPR119AR | |
| SCHEMBL1796811 | 0.81 | CHRNA7 (0.58) | NR1H2NR1H3AR | |
| SCHEMBL24681357 | 0.80 | GPR119 (0.43) | NR1H2NR1H3GPR119ARRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | NR1H2 158/4885NR1H3 202/4885GPR119 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.